Absci Corporation (ABSI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Core Insights - The company is focused on generative design leveraging AI to tackle challenging problems in drug discovery, specifically targeting hard-to-drug areas like ion channels and GPCRs [1] - AI is seen as a tool to reduce timelines and costs while also enabling the exploration of novel biological targets that other technologies cannot address [1] Partnerships and Pipeline - The company has established partnerships with major pharmaceutical firms such as Merck, AstraZeneca, and Almirall, indicating strong industry collaboration [2] - The internal pipeline is focused on inflammation and immunology (I&I), with the first asset currently in clinical trials and a Phase Ia readout expected in the coming months [2]